Oncotelic Therapeutics Inc · OTC:OTLC
Oncotelic Therapeutics — Mateon Therapeutics — Investor Presentation (October 2019)
15 slides from Oncotelic Therapeutics's investor presentation, Oct 29, 2019
Slide 1: Oncotelic: Building the next generation Biotech
— SS ONCOTELIC Building the next generation Biotech TRABEDERSEN-DRUG DEVELOPMENT USING PHOSPHOROTHIOATE ANTISENSE PLATFORM MATEON THERAPEUTICS
Slide 2: Forward-looking Statements
Forward-looking Statements This document contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in thi
Slide 3: The Three Convergents
The Three Convergents —— QT 2 —é —_ PointR.a ONCOTELIC Supercom puting MATEON THERAPEUTICS
Slide 4: Antisense Therapeutics
ae Antisense Therapeutics Aclass of RNA Therapeutics that inhibit the translation of the target protein- ie. TGF-beta2 DEDAADP a MATEON THERAPEUTICS
Slide 5: Antisense as Next Generation Drugs
Antisense as Next Generation Drugs te | Attributes | smallMolecules [mab [Antisense | Inception 1850s to present 1920s to present 1990s to present Size 200-500 >150,000 5,000 to 7,000 Drug Discovery Random screening Focused screening Rationally designed Success Rate Low-~5% Moderate-~50% High-~90% P
Slide 6: Antisense Oligonucleotide Molecules
—~ Antisense Oligonucleotide Molecules > Single stranded (13- to 25-mer) DNA molecules (oligodeoxynucleotides) > Specifically inhibit target protein expression via complementary hybridization to relevant MRNA —_,-3° Antisense oligonucleotide , — pets ren eesti —»> — * RNAse H-mediated cleavage of ta
Slide 7: Oligonucleotide Chemistry 101
—~ “Oligonucleotide Chemistry 101’ : Phosphodiester bonds Phosphorothioate bonds + higher resistance to nucleases (@ stability) MATEON THERAPEUTICS
Slide 8: FDA has approved several ASO
FDA has approved several ASO **1) Fomivirsen: for treatment of patients with cytomegalovirus (CMV) retinitis “*2) Macugen: for age-related macular degeneration (AMD) of the retina “¢3) Mipomersen: for homozygous familial hypercholesterolemia (HoFH) “*4) Nusinersen/Spinraza- for spinal muscular atrop
Slide 9: TGF-B as a Target
SS TGF-B as a Target oe food The overexpression of transforming growth factor-beta, specifically TGF-B2, plays a key role in malignant progression of various tumors by inducing proliferation, metastasis, angiogenesis, and immunosuppression “ Therefore, reducing TGF-B2 expression has a very high clin
Slide 10: OT-101: Drug Product - TGF-B2 Antisense
— EE OT-101: Drug Product- TGF-82 Antisense. ** Trabedersen (OT-101) is a single-stranded phosphorothioate antisense oligodeoxynucleotide (18-mer) targeting the human TGF-B2 messenger RNA “* Ready for registration trials--Over 200 patients treated across 6 clinical trials “* Potential for breakthrou
Slide 11: Single Agent Activity - Glioblastoma
—— Se Single Agent Activity- Glioblastoma: % GO04-Phase 2b trial “ Title: A multi-national, multi-center, open-label, active-controlled, randomized parallel-group dose-finding study to evaluate the efficacy and safety of two doses of OT-101 in adult patients with recurrent high- grade glioma, admini
Slide 12: Clinical Efficacy: Objective Responses
Clinical Efficacy: Objective Responses “<n Tumor Volume fo2} Oo 500 1000 1500 2000 OT-101 CR OT-101 PR OT-101 SD OT-101 PD Percent survival 2500 110 100 “* Objective responses were observed among the 87 evaluable patients treated with OT-101: “* Best Objective Responses were: 5 CR (5.9%), 14 PR (16.
Slide 13: Single Agent Activity - Pancreatic Cancer
Single Agent Activity- Pancreatic Cancer RY x 4 % POO1- Phase 1/2 Clinical Trial Title: An Open-Label, Multicenter Dose-escalation Study to Evaluate the Safety and Tolerability of OT- 101 (TGF-B2-specific Phosphorothioate Antisense Oligodeoxynucleotide), Administered Intravenously in Adult Patients
Slide 14: P001 Phase 1/2 Trial
———— P001 Phase 1/2 Trial Patient 1006: CR as far out as 77 mos Patient 1022: OS of 40 months Surgery: Whipple’s procedure Surgery: Whipple’s procedure 1% line: 5-FU/LV, Dose 425 mg/m2 1% line: Radiation therapy (50 Gy) 24 line: 5-FU/LV, Dose 2600 mg/m2/24hr 2"4 jine: SFU 34 line: Gemcitabine, Dose
Slide 15: Mateon/Oncotelic (MATN) - Building the Next Generation
Mateon/Oncotelic- (MATN)- Building The Next Genera ion ——~ Pharma — —e aes <i NAVIGATOR DATA PIPELINE Large Data Analytics Large Clinical Data High Value Pipeline MATEON » Thank You THERAPEUTICS
Mateon Therapeutics — Investor Presentation (October 2019) on 6ix